Putative drug binding conformations of monoamine transporters.

Structural information about monoamine transporters and their interactions with psychotropic drugs is important for understanding their molecular mechanisms of action and for drug development. The crystal structure of a Major Facilitator Superfamily (MFS) transporter, the lactose permease symporter (lac permease), has provided insight into the three-dimensional structure and mechanisms of secondary transporters. Based on the hypothesis that the 12 transmembrane alpha-helix (TMH) secondary transporters belong to a common folding class, the lac permease structure was used for molecular modeling of the serotonin transporter (SERT), the dopamine transporter (DAT), and the noradrenaline transporter (NET). The molecular modeling methods used included amino acid sequence alignment, homology modeling, and molecular mechanical energy calculations. The lac permease crystal structure has an inward-facing conformation, and construction of outward-facing SERT, DAT, and NET conformations allowing ligand binding was the most challenging step of the modeling procedure. The psychomotor stimulants cocaine and S-amphetamine, and the selective serotonin reuptake inhibitor (SSRI) S-citalopram, were docked into putative binding sites on the transporters to examine their molecular binding mechanisms. In the inward-facing conformation of SERT the translocation pore was closed towards the extracellular side by hydrophobic interactions between the conserved amino acids Phe105, Pro106, Phe117, and Ala372. An unconserved amino acid, Asp499 in TMH10 in NET, may contribute to the low affinity of S-citalopram to NET.

[1]  G. Uhl,et al.  Dopamine transporter mutants selectively enhance MPP+ transport , 1993, Synapse.

[2]  S Kitayama,et al.  Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[3]  G. Uhl,et al.  Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition. , 1999, Molecular pharmacology.

[4]  S G Dahl,et al.  Molecular model of the Escherichia coli Na1/H1 antiporter NhaA. , 2001, Receptors & channels.

[5]  Da-Neng Wang,et al.  Structure and Mechanism of the Glycerol-3-Phosphate Transporter from Escherichia coli , 2003, Science.

[6]  H. Kaback,et al.  From membrane to molecule to the third amino acid from the left with a membrane transport protein , 1997, Quarterly Reviews of Biophysics.

[7]  B. S. Park,et al.  Importance of valine at position 152 for the substrate transport and 2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane binding of dopamine transporter. , 2000, Molecular pharmacology.

[8]  Ruben Abagyan,et al.  ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation , 1994, J. Comput. Chem..

[9]  R. Blakely,et al.  Pharmacological profile of antidepressants and related compounds at human monoamine transporters. , 1997, European journal of pharmacology.

[10]  Randy D. Blakely,et al.  Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter , 1991, Nature.

[11]  R. Blakely,et al.  High Affinity Recognition of Serotonin Transporter Antagonists Defined by Species-scanning Mutagenesis , 1998, The Journal of Biological Chemistry.

[12]  O. Wiborg,et al.  Mutational scanning of the human serotonin transporter reveals fast translocating serotonin transporter mutants , 2004, The European journal of neuroscience.

[13]  R. Blakely,et al.  Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Iwata,et al.  Structure and Mechanism of the Lactose Permease of Escherichia coli , 2003, Science.

[15]  Ingebrigt Sylte,et al.  Molecular Mechanism of Citalopram and Cocaine Interactions with Neurotransmitter Transporters , 2003, Journal of Pharmacology and Experimental Therapeutics.

[16]  M. Saier,et al.  A functional superfamily of sodium/solute symporters. , 1994, Biochimica et biophysica acta.

[17]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[18]  A. Ravna,et al.  Structures and Models of Transporter Proteins , 2004, Journal of Pharmacology and Experimental Therapeutics.

[19]  E. Pebay-Peyroula,et al.  X-ray structure of bacteriorhodopsin at 2.5 angstroms from microcrystals grown in lipidic cubic phases. , 1997, Science.

[20]  M. Caron,et al.  Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. , 1992, Molecular pharmacology.

[21]  F. Bloom,et al.  Psychopharmacology: The Fourth Generation of Progress , 1995 .

[22]  J Hoflack,et al.  Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. , 1991, Molecular pharmacology.

[23]  Ingebrigt Sylte,et al.  Molecular model of the neural dopamine transporter , 2003, J. Comput. Aided Mol. Des..

[24]  G. Rudnick,et al.  The Third Transmembrane Domain of the Serotonin Transporter Contains Residues Associated with Substrate and Cocaine Binding* , 1997, The Journal of Biological Chemistry.

[25]  M. Caron,et al.  Oligomerization and Trafficking of the Human Dopamine Transporter , 2003, The Journal of Biological Chemistry.

[26]  S Kitayama,et al.  Dissection of Dopamine and Cocaine Binding Sites on the Rat Dopamine Transporter Expressed in COS Cells a , 1996, Annals of the New York Academy of Sciences.

[27]  J. Javitch,et al.  Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S Kitayama,et al.  Tyrosine-533 of rat dopamine transporter: involvement in interactions with 1-methyl-4-phenylpyridinium and cocaine. , 1998, Brain research. Molecular brain research.

[29]  J. Steed,et al.  A highly efficient, preorganized macrobicyclic receptor for halides based on CH... and NH...anion interactions. , 2004, Journal of the American Chemical Society.

[30]  A. Ravna,et al.  A putative three-dimensional arrangement of the human serotonin transporter transmembrane helices: a tool to aid experimental studies. , 2001, Journal of molecular graphics & modelling.

[31]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[32]  Eric L. Barker,et al.  Transmembrane Domain I Contributes to the Permeation Pathway for Serotonin and Ions in the Serotonin Transporter , 1999, The Journal of Neuroscience.

[33]  E. Padan,et al.  Topological Analysis of NhaA, a Na+/H+ Antiporter from Escherichia coli* , 1996, The Journal of Biological Chemistry.

[34]  Richard A. Lerner,et al.  Crystal structure of a bacterial cocaine esterase , 2002, Nature Structural Biology.

[35]  B. Elfving,et al.  The Chicken Serotonin Transporter Discriminates between Serotonin-selective Reuptake Inhibitors , 2004, Journal of Biological Chemistry.

[36]  K. Williams,et al.  Three-dimensional structure of the ion-coupled transport protein NhaA , 2000, Nature.

[37]  G R Marshall,et al.  Novel approach to computer modeling of seven-helical transmembrane proteins: current progress in the test case of bacteriorhodopsin. , 2001, Acta biochimica Polonica.

[38]  D. Murphy,et al.  Isolation of a cDNA encoding the human brain serotonin transporter , 2005, Journal of Neural Transmission / General Section JNT.

[39]  A. S. Chang,et al.  Possible existence of quaternary structure in the high-affinity serotonin transport complex. , 1998, Biochemical and biophysical research communications.